University of Illinois
Chicago IL
MD - Medicine
1971
University of Wisconsin
Madison WI
BS - Liberal Arts
1967
Oligometastases: Characterizing the Role of Epigenetic Regulation of Epithelial-Mesenchymal Transition.
Oligometastases: Characterizing the Role of Epigenetic Regulation of Epithelial-Mesenchymal Transition. Clin Cancer Res. 2023 08 01; 29(15):2761-2766.
PMID: 37115507
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial.
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial. JAMA Oncol. 2023 Jul 20.
PMID: 37471075
YTHDF2/m6 A/NF-?B axis controls anti-tumor immunity by regulating intratumoral Tregs.
YTHDF2/m6 A/NF-?B axis controls anti-tumor immunity by regulating intratumoral Tregs. EMBO J. 2023 08 01; 42(15):e113126.
PMID: 37345898
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. Oncoimmunology. 2023; 12(1):2222560.
PMID: 37363104
YTHDF2 inhibition potentiates radiotherapy antitumor efficacy.
YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 07 10; 41(7):1294-1308.e8.
PMID: 37236197
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023 05 15; 133(10).
PMID: 37183819
Nanoparticle-Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy.
Nanoparticle-Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy. Adv Mater. 2023 May; 35(21):e2206370.
PMID: 36524978
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292.
PMID: 35851593
Author Correction: Tumor aneuploidy predicts survival following immunotherapy across multiple cancers.
Author Correction: Tumor aneuploidy predicts survival following immunotherapy across multiple cancers. Nat Genet. 2023 Feb; 55(2):355.
PMID: 36596861
A Three-in-One Nanoscale Coordination Polymer for Potent Chemo-Immunotherapy.
A Three-in-One Nanoscale Coordination Polymer for Potent Chemo-Immunotherapy. Small Methods. 2023 05; 7(5):e2201437.
PMID: 36638256